Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis

Lopez, Anthony; Mariette, Xavier; Bachelez, Hervé; Belot, Alexandre; Bonnotte, Bernard; Hachulla, É.; Lahfa, Morad; Lortholary, Olivier; Loulergue, Pierre; Paul, Stéphane; Roblin, Xavier; Sibilia, Jean; Blum, Mariela A.; Danese, Silvio; Bonovas, Stefanos; Peyrin–Biroulet, Laurent

doi:10.1016/j.jaut.2017.03.011

Cited by 120 publications

(88 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference might be, at least partially, explained by a lower HIV prevalence in our patients. Although seasonal influenza vaccinations have been recommended for adults with immunosuppressive conditions [33], only a few studies have evaluated the IVE against clinical outcomes among this population [34]. Our finding provides supporting evidence for the current recommendations but needs to be confirmed in future studies.…”

Section: Immunosuppressive Conditions and Statinssupporting

confidence: 55%

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Suzuki

Katsurada

et al. 2018

Vaccine

View full text Add to dashboard Cite

Section: Immunosuppressive Conditions and Statinssupporting

confidence: 55%

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Suzuki

Katsurada

et al. 2018

Vaccine

View full text Add to dashboard Cite

“…To optimize their care, candidates need a comprehensive evaluation before transplantation regarding preventable infectious diseases. One of the most important steps of prevention is immunization against highly contagious lethal diseases . These infections cause not only life‐threatening complications to the SOT recipient but also increase the incidence of graft rejection and loss .…”

Section: Introductionmentioning

confidence: 99%

Serologic screening and infectious disease consultation (IDC): Indicated in heart, lung, liver (HLL) solid organ transplants (SOT) for measles, mumps, rubella, and varicella

Seckin

Brumble

Libertin

2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Background Solid organ transplant (SOT) recipients are a special group of patients who require comprehensive evaluation for preventable infectious diseases before transplantation. The main aim of our study was to investigate the number of heart, lung, and liver (HLL) transplant recipients who were evaluated for their immune status against measles, mumps, rubella (MMR), and varicella (VZV). As a secondary aim, we investigated whether pre‐transplant infectious disease consultation (IDC) improves vaccination rates. Methods This study was an institution‐based retrospective analysis of HLL transplant recipients born in or after 1957 and evaluated at Mayo Clinic, FL Transplant Center between January 1st, 2016 and December 31st, 2017. Data collection was obtained from electronic medical records. The vaccination rates were compared by univariate analysis based on IDC and no ID consultation (NIDC). Results One hundred and eighty‐seven (77%) of a total 242 patients received an IDC pre‐transplantation. Varicella IgG levels were screened in all 187 IDC candidates. Among the 187 IDC patients, mumps, measles, and rubella IgG serologies were performed in 9 (5%), 21 (11%), and 51 (27%), respectively. Among all 242 patients, vaccines given included 2 (0.8%) MMR, 10 (4.1%) varicella and 85 (35.12%) Zostavax. Univariate analysis revealed that Zostavax was given to 76 (40.6%) pre‐transplant IDC patients and only in 9 (16.7%) NIDC patients (P < .001). Conclusions Despite the relatively high IDC rate, patients’ screened numbers for MMR IgG levels were low. Results pointed out the need for MMR protocol‐driven serologic screening as well as for VZV and IDC prior to transplantation to increase vaccination rates.

show abstract

“…Contrary to the advice by Wong et al, 1 vaccination with live vaccines, such as the live herpes zoster vaccine, is not recommended for people being treated with leflunomide, nor should a live vaccine be given sooner than a period of at least 6 months has elapsed after stopping leflunomide. [2][3][4] Leflunomide has a long half-life. There are no clinical data on the safety of vaccination with live vaccines during treatment with leflunomide.…”

Section: No Live Vaccines For People Being Treated With Leflunomidementioning

confidence: 99%

Regulation of e‐cigarettes

Thomas

Chow

Thiagalingam

2018

Internal Medicine Journal

View full text Add to dashboard Cite

Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis

Cited by 120 publications

References 47 publications

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Serologic screening and infectious disease consultation (IDC): Indicated in heart, lung, liver (HLL) solid organ transplants (SOT) for measles, mumps, rubella, and varicella

Regulation of e‐cigarettes

Contact Info

Product

Resources

About

Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis

Cited by 120 publications

References 47 publications

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Serologic screening and infectious disease consultation (IDC): Indicated in heart, lung, liver (HLL) solid organ transplants (SOT) for measles, mumps, rubella, and varicella

Regulation of e‐cigarettes

Contact Info

Product

Resources

About

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan

Effectiveness of inactivated influenza vaccine against laboratory-confirmed influenza pneumonia among adults aged ≥65 years in Japan